The soft tissue sarcoma market across the 7MM is growing driven by increasing disease recognition, improved diagnostic practices, and growing research activity supporting the development of novel therapeutic approaches, including TBI-1301 (mipetresgene autoleucel) (Takara Bio), INT230-6 (Intensity Therapeutics),…

Read the full release →

News provided by PR Newswire.